TAIZHOU, China, Apr. 2, 2019 /PRNewswire/ -- China SXT
Pharmaceuticals, Inc. (the "Company") (NASDAQ:SXTC), a
specialty pharmaceutical company focusing on the research,
development, manufacture, marketing and sales of Traditional
Chinese Medicine Pieces ("TCMPs"), announced today that its VIE
subsidiary, Jiangsu Suxuantang Pharmaceutical Co., Ltd. ("Taizhou
Suxuantang"), has been certified as National High-tech Enterprise
(the "Certification") by the Ministry of Science and
Technology of the PRC. The Certification is valid for three years
and allows Taizhou Suxuantang to enjoy a preferential income tax
rate of 15% versus the standard rate of 25%.
About China SXT Pharmaceuticals, Inc.
Incorporated in 2005 and headquartered in Taizhou City,
Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an
innovative pharmaceutical company based focusing on the research,
development, manufacture, marketing and sales of traditional
Chinese medicine pieces, which is a type of Traditional Chinese
Medicine that has been processed to be ready for use. For more
information, please visit www.sxtchina.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of
future performance and involve risks and uncertainties that may
cause the actual results to differ materially from the Company's
expectations discussed in the forward-looking statements. These
statements are subject to uncertainties and risks including, but
not limited to, the following: the Company's goals and
strategies; the Company's future business development; product and
service demand and acceptance; changes in technology; the growth of
the pharmaceutical market, particularly the Traditional Chinese
Medicine Pieces ("TCMPs") market, in China; reputation and brand; the impact of
competition and pricing; government regulations; fluctuations in
general economic and business conditions in China and the international markets the
Company serves and assumptions underlying or related to any of the
foregoing and other risks contained in reports filed by the Company
with the Securities and Exchange Commission. For these
reasons, among others, investors are cautioned not to place undue
reliance upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings with the
U.S. Securities and Exchange Commission, which are available for
review at www.sec.gov. The Company undertakes no obligation to
publicly revise these forward‐looking statements to
reflect events or circumstances that arise after the date
hereof.
For more information, please contact:
At the Company:
Alex Shi, CFO
Email: ir@sxtchina.com
Investor Relations:
Tony Tian,
CFA
Weitian Group LLC
Email: ttian@weitianco.com
Phone: +1 732-910-9692
View original
content:http://www.prnewswire.com/news-releases/china-sxt-pharmaceuticals-inc-receives-national-high-tech-enterprise-qualification-300822518.html
SOURCE China SXT Pharmaceuticals, Inc.